Collaborations and License Agreements - Additional Information (Detail)	1 Months Ended									3 Months Ended											12 Months Ended
	Aug. 31, 2015 USD ($)	Nov. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Jul. 31, 2012 USD ($)	Feb. 28, 2011 USD ($)	Mar. 31, 2010 USD ($)	Mar. 31, 2009 USD ($)	Dec. 31, 2006 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Jun. 30, 2011 USD ($)	Mar. 31, 2011 USD ($)	Mar. 31, 2010 USD ($)	Dec. 31, 2015 USD ($) Indication	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Apr. 30, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue										$ 3,598,000	$ 15,158,000	$ 134,000	$ 134,000	$ 115,000	$ 873,000	$ 1,846,000	$ 15,289,000				$ 19,024,000	$ 18,123,000	$ 1,293,000
Amounts due from pursuant to the cost-sharing provisions										$ 4,641,000				2,341,000							4,641,000	2,341,000
Research and development																					12,875,000	38,254,000	68,468,000
Credited against amounts due the Company for tenant improvements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales-based milestones payment																					22,500,000
Will be paid in nine equal monthly installments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales-based milestones payment																					5,500,000
Scenario 3
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales-based milestones payment																					4,200,000
Other License Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development																					25,000
License payment per product																					1,000,000
License expense																					$ 0	0	0
Other License Agreements | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, royalties payment on net sales										1.50%											1.50%
Other License Agreements | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, royalties payment on net sales										0.50%											0.50%
Option and License Agreement | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																					$ 6,000,000
EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development funding received																					2,500,000
Collaborations and license agreements, expected milestone receivable																					4,000,000
Payments received in connection with indications																					$ 2,000,000
Eligible number of indications | Indication																					3
Payments received in connection with additional indications																					$ 5,000,000
Potential payments received in connection with additional indications																					$ 335,000,000
License agreement date																					Dec. 21, 2006
Collaborations and license agreements, written notice period for termination																					30 days
Collaborations and license agreements, milestone payment received																					$ 14,000
EUSA | Utilization of Data Generated by Planned Phase Three Study
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received										$ 20,000,000											20,000,000
EUSA | Potential Phase One Combination Study
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received										2,000,000											2,000,000
EUSA | Marketing Approval in France, Germany, Italy, Spain and the United Kingdom
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received										2,000,000											2,000,000
EUSA | Marketing Approval in Argentina, Australia, Brazil, South Africa and Venezuela
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received										2,000,000											$ 2,000,000
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable	$ 15,000,000
Period for payment of license fees																					15 days
Reimbursable inventory	3,500,000
License and service revenue																					$ 15,000,000
Upfront license payment																					15,000,000
Collaboration revenue																					3,500,000
Amounts due from pursuant to the cost-sharing provisions										3,500,000											3,500,000
Novartis | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																					150,000,000
Novartis | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																					53,000,000
Novartis | Regulatory Milestone Events
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																					$ 105,000,000
Pharmstandard
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable	1,500,000
Period for payment of license fees																					15 days
Upfront license payment											1,000,000
Collaboration revenue																					$ 61,000
Allocation of upfront payment																					1,000,000
Pharmstandard | Receivable within fifteen business days of the date the license agreement is registered with the Federal Service for Intellectual Property of the Russian Federation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable											$ 500,000
Pharmstandard | Receivable With First Marketing Authorization
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable	7,500,000
Pharmstandard | Receivable If Additional Regulatory Studies Required Prior To Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable	3,000,000
Pharmstandard | Receivable For Each Additional Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable	$ 3,000,000
Kyowa Hakko Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Expense associated with sublicensing fees payable																					300,000
Ophthotech Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
One time option exercise fee																					2,000,000
Ophthotech Corporation | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received																					45,000,000
Ophthotech Corporation | Phase Two Clinical Trials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received																					10,000,000
Ophthotech Corporation | Marketing Approval in the United States
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received																					20,000,000
Ophthotech Corporation | Marketing Approval in the UK, Germany, Spain, Italy and France
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received																					$ 20,000,000
Ophthotech Corporation | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, written notice period for termination																					90 days
Ophthotech Corporation | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront license payment		$ 500,000
License expiration period		2017-02
Collaborations and license agreements, payment received																						500,000
Collaborations and license agreements, revenue recognized																					$ 200,000	38,000
Ophthotech Corporation | Option and License Agreement | Ind Submission Milestone Payment
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																					2,000,000
Biodesix | N S C L C P O C Trial
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions										1,100,000				1,800,000							1,100,000	1,800,000
Responsible percentage of development and regulatory costs after cap reached																										50.00%
Collaborations and license agreements, royalties payment on net sales																										10.00%
Biodesix | N S C L C P O C Trial | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																					3,500,000	2,700,000
Biodesix | N S C L C P O C Trial | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding																										$ 15,000,000
Biogen Idec International GmbH
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, revenue recognized			$ 14,100,000
Collaborations and license agreements, deferred revenue			14,700,000														$ 14,700,000
Collaborations and license agreements, relative selling price of the deliverable			$ 600,000
Biogen Idec International GmbH | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payments																					50,000,000
Biogen Idec International GmbH | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received																		$ 10,000,000		$ 10,000,000
Collaborations and license agreements, payment received								$ 20,000,000
Collaborations and license agreements, revenue recognized																					300,000	14,500,000	900,000
Amortization of deferred revenue																					10,000,000
Astellas Pharma Inc. | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront license payment						$ 97,600,000
Amounts due from pursuant to the cost-sharing provisions										$ 100,000				$ 600,000							100,000	600,000
Collaborations and license agreements, payment received						125,000,000
Collaborations and license agreements, relative selling price of the deliverable																			$ 125,000,000
Collaborations and license agreements, discount rate																			15.00%
Astellas Pharma Inc. | Astellas Agreement | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																					700,000	3,500,000	15,800,000
Astellas Pharma Inc. | Astellas Agreement | General and administrative
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																					100,000	100,000	2,800,000
Astellas Pharma Inc. | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, payment received																					1,500,000	4,100,000	40,100,000
Collaborations and license agreements, revenue recognized																					0	3,600,000	400,000
Astellas Pharma Inc. | Regulatory Milestone Events | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, payment received				$ 15,000,000
Astellas Pharma Inc. | Up-front Payment Arrangement | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, payment received						75,000,000
Astellas Pharma Inc. | research and development funding | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, payment received						$ 50,000,000
Astellas Pharma Inc. | License Deliverable | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, revenue recognized																			$ 120,200,000
Collaborations and license agreements, relative selling price of the deliverable																					120,200,000
Astellas Pharma Inc. | Royalty Territory Deliverable | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, revenue recognized																					0	3,600,000	$ 400,000
Collaborations and license agreements, deferred revenue																			$ 4,800,000
Collaborations and license agreements, relative selling price of the deliverable																					$ 4,800,000
Collaborations and license agreements, revenue recognized																						$ 3,100,000
Collaborations and license agreements, deferred revenue recognition period																					through April 2022
Kirin Brewery Co. Ltd. | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment				$ 12,000,000
Reimbursement cost																								$ 6,000,000
Kirin Brewery Co. Ltd. | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, cash payment									$ 5,000,000
Collaborations and license agreements, milestone payment							$ 10,000,000
Research and development																									$ 22,500,000
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements									30.00%
Kirin Brewery Co. Ltd. | FDA Marketing Approval | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, potential future milestone payments, maximum amount									$ 18,000,000
St Vincent's Hospital Sydney Limited | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, potential future milestone payments, maximum amount					$ 18,900,000
Collaborations and license agreements, time period from first commercial sale of certain product upon which the agreement expires					10 years
Termination period in case of breach of contract					4 months
St Vincent's Hospital Sydney Limited | Up-front Payment Arrangement | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, cash payment					$ 700,000																$ 1,500,000
St Vincent's Hospital Sydney Limited | MIC-1 research and development programs | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, written notice period for termination					6 months